Axicabtagene ciloleucel

Status:
Do Not Prescribe (DNP), Red
Decision Date:
February 2019
 

Comments

RED:

  • Treatment of adults with relapsed or refractory follicular lymphoma after ≥3 lines of systemic therapy. (NHSE commissioned).  (Decision date - October 2022)
  • NICE TA872 - for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies (Decision date - March 2023)
  • NICE TA895 - Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy. (Decision date - July 2023)

DNP:

  •  NICE TA894 - Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma. (Decision date - July 2023)

Red Drug Classifications

  • 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
  • 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
  • 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
  • 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app